Class action by businesses in the complementary medicines industry

We successfully defended a class action against five individual officers of the Therapeutic Goods Administration (TGA) worth in excess of $150 million. The class action was brought by 169 businesses in the complementary medicines industry who alleged substantial losses following the suspension by the TGA of the manufacturing licence of Pan Pharmaceuticals and subsequent recall of products. The litigation raised issues concerning the conduct of representative proceedings and involved a complex factual matrix which necessitated a labour intensive forensic factual investigation and assessment. A court-ordered mediation extending over four days resulted in a settlement of the action. The settlement was approved by the Federal Court of Australia. There was no finding nor concession of any wrongdoing by our clients. The compensation paid to the represented class of applicants was provided by the Commonwealth of Australia, which was the first respondent in the proceedings.


Related Articles

NO LONGER PART OF THE GROUP: IT MAY NOT BE TOO LATE

Legal Directions

Murray v Great Southern Managers Australia Ltd [2018] VSC 416 Facts In August 2011, a group proceeding was commenced on behalf…

Continue reading

INTENTIONAL, BUT STILL WRONGFUL: INTERPRETATION OF A PROFESSIONAL INDEMNITY POLICY

Legal Directions

Introduction In its recent decision in Underwriters at Lloyds v Aquagenics Pty Ltd (in liquidation) [2018] FCAFC 9, the Full Federal…

Continue reading

EVERY CASE TURNS ON ITS FACTS

Legal Directions

Jancevski v WR Engineering Pty Ltd [2018] ACT CA 34 Background The plaintiff was engaged by the defendant to install garage…

Continue reading